News

Researchers from Leavitt Partners are using a combination of public and proprietary data to report on some early findings about ACOs.

The industry is awaiting the Supreme Court’s ruling on Universal Health Services v. Escobar. This case concerns the viability of the “implied certification” theory of legal falsity under the False Claims Act.

The combination of unsustainable healthcare spending and the rapid growth of value-based reimbursement revenue models is driving the shift to patient-centered care across the continuum-or continuum-centered care.

Advancements in treatment show cancer trending towards a chronic condition. Align your cancer chronic care management team now. Here’s how. Advancements in treatment show cancer trending towards a chronic condition. Align your cancer chronic care management team now. Here's how.

A look at some of the technology advances at one hospital, and across the country, that are changing the way pediatric cancer patients are treated.

Healthcare organizations are looking for new ways to engage consumers, streamline information sharing and transparency and collaborate with other industry stakeholders. As a result, healthcare stakeholders need to focus on three key strategies.

Nivolumab (Opdivo, Bristol-Myers Squibb) received two new approvals from FDA to treat two different cancers.

How approaching the open-enrollment process with a customer-centric mindset promotes member retention.

After heavy criticism by Congress, presidential candidates and others, Valeant Pharmaceuticals is offering a discount program on its heart drugs Nitropress and Isuprel.

There's a growing need for improved access to medication-assisted treatment among patients with opioid use disorder, according to a new study presented at the American Society of Addiction Medicine 47th Annual Conference.

If a proposed Vermont bill is successful, drug companies would have to explain why they hiked prices on certain drugs.

A recent survey reveals how generational differences affect consumers’ health plan and provider preferences and selections.

Creating a national data policy framework for empowered consumer choices.

With new requirements from CMS on the horizon, how will the shift to value-based care impact consumers, payers, and providers?

FDA issued a new warning about potentially serious side effects associated with fluoroquinolone antibacterial drugs. Affected brands include Cipro, Levaquin, Avelox, Factive and Moxaflaxacin injection, as well as the generic Ofloxacin.

As pharmaceutical companies of all sizes continue to adapt to the ongoing internal and external pressures of the new health economy, it remains imperative that strategy maintain distinct capabilities to position the company ahead of its competitors.

Insights from the 2016 edition of the largest gathering in specialty pharmacy.

Hep C virus testing supports value of diagnostics in precision medicine.

FDA is warning that the antipsychotic medicine olanzapine can cause a rare but serious skin reaction that can progress to affect other parts of the body.

MACRA, which will further the shift to value-based reimbursement, has industry insiders grappling with the complexities, particularly those related to reporting guidelines for providers.

An expansion of the ACA requires health plans to cover a new preventive service: Regular nutritional counseling for millions of overweight Americans with other health risks.

Health insurance coverage remains a huge challenge for small businesses due to cost. Health plan providers and brokers are in a unique position to address these challenges and target the working uninsured with affordable options for coverage.

Colorado could have the first statewide universal healthcare system in the country if proposed legislation passes in November. Will it happen? Experts weigh in.

Insight from Paul Markovich, CEO, Blue Shield of California

Looking back on your career, what advice do you wish you had starting out? Here’s what our editorial advisory board said.

FDA recently fast-tracked approval of cabozantinib (Cabometyx, Exelixis, Inc.) to treat advanced renal cell carcinoma. Here are the top 5 facts to know about Cabometyx.

Cardiovascular drugs are among the most widely used, since their indications are far reaching and address conditions that are prevalent among a large population.

Express Scripts will implement more programs that pay for drugs based on their effectiveness, according to the PBM’s chief medical officer Steve Miller, MD. Simultaneously, the PBM plans to implement a spending cap on diabetes medications.

Doug Chaet, senior vice president, Provider Networks and Value-Based Solutions at Independence Blue Cross, shares five strategies that can help providers succeed in value-based reimbursement models.

Democratic presidential candidate Hillary Clinton vows to provide more affordable, cost effective, accessible, and higher quality healthcare and insurance coverage. Here’s a closer look at seven key ways Clinton would change the healthcare system if elected president.